Primatene Mist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8367734 ARMSTRONG PHARMS Stable epinephrine suspension formulation with high inhalation delivery efficiency
Jan, 2026

(2 years from now)

Primatene Mist is owned by Armstrong Pharms.

Primatene Mist contains Epinephrine.

Primatene Mist has a total of 1 drug patent out of which 0 drug patents have expired.

Primatene Mist was authorised for market use on 07 November, 2018.

Primatene Mist is available in aerosol, metered;inhalation dosage forms.

The generics of Primatene Mist are possible to be released after 26 January, 2026.

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 07 November, 2018

Treatment: NA


More Information on Dosage

PRIMATENE MIST family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic